43 results on '"Madanchi M"'
Search Results
2. The diagnostic accuracy of experienced physicians to clinically discriminate type 1 myocardial infarction from type 2 myocardial infarction or myocardial injury
- Author
-
Bossard, M, primary, Nestelberger, T, additional, Kaiser, C, additional, Gschwend, M, additional, Madanchi, M, additional, Reichlin, T, additional, Toggweiler, S, additional, Majcen, I, additional, Kobza, R, additional, Osswald, S, additional, Cuculi, F, additional, and Mueller, C, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Treatment of microvascular angina with the coronary sinus reducer: a first experience
- Author
-
Gnan, E, primary, Cioffi, G M, additional, Bossard, M, additional, Madanchi, M, additional, Majcen, I, additional, Zhi, Y, additional, Gjergjizi, V, additional, Seiler, T, additional, Cuculi, F, additional, and Attinger, A, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Treatment of coronary artery disease with sirolimus- versus paclitaxel-coated balloons
- Author
-
Cuculi, F, primary, Madanchi, M, additional, Cioffi, G M, additional, Majcen, I, additional, Gnan, E, additional, Gjergjizi, V, additional, Zhi, Y, additional, Seiler, T, additional, Attinger-Toller, A, additional, and Bossard, M, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Direct oral anticoagulants compared to vitamin K-antagonists in patients with left ventricular thrombus
- Author
-
Seiler, T, primary, Vasiliauskaite, E, additional, Cioffi, G M, additional, Madanchi, M, additional, Attinger, A, additional, Staempfli, S F, additional, De Boeck, B, additional, Kobza, R, additional, Toggweiler, S, additional, Moccetti, F, additional, Wolfrum, M, additional, Suter, Y, additional, Grueter, D, additional, Cuculi, F, additional, and Bossard, M, additional
- Published
- 2022
- Full Text
- View/download PDF
6. P525 A prospective interventional study to evaluate the effect of hypoxia on healthy volunteers and patients with inflammatory bowel disease: The altitude IBD study
- Author
-
Vavricka, S, primary, Zeitz, J, additional, Madanchi, M, additional, Biedermann, L, additional, Morsy, Y, additional, Scharl, M, additional, Gassmann, M, additional, Lutz, T, additional, Kunz, A, additional, Bron, D, additional, Rogler, G, additional, and Greuter, T, additional
- Published
- 2022
- Full Text
- View/download PDF
7. Utility and safety of the MANTA device for access site closure after removal of the mechanical hemodynamic support device Impella on the intensive care unit
- Author
-
Burkart, P, primary, Bossard, M, additional, Moccetti, F, additional, Hess, S, additional, Jeyarasa, M, additional, Madanchi, M, additional, Cioffi, G, additional, Seiler, T, additional, Wolfrum, M, additional, Hakimi, M, additional, Seelos, R, additional, Toggweiler, S, additional, Attinger-Toller, A, additional, Kobza, R, additional, and Cuculi, F, additional
- Published
- 2021
- Full Text
- View/download PDF
8. Hypoxia positively regulates the expression of pH-sensing G-protein – coupled receptor OGR1 (GPR68)
- Author
-
De Vallière, Cheryl, Zeitz, J, Cosin-Roger, S, Ruiz, P A, Atrott, K, Wagner, C A, Seuwen, K, Fried, M, Tcymbarevich, I, Kullak-Ublick, G A, Misselwitz, B, Rogler, G, Melhem, H, Madanchi, M, Vavricka, S R, and Eloranta, J J
- Published
- 2016
- Full Text
- View/download PDF
9. Hypoxia Positively Regulates the Expression of pH-Sensing G-Protein-Coupled Receptor OGR1 (GPR68)
- Author
-
de Valliere C, Cosin-Roger J, Simmen S, Atrott K, Melhem H, Zeitz J, Madanchi M, Tcymbarevich I, Fried M, Kullak-Ublick G, Vavricka S, Misselwitz B, Seuwen K, Wagner C, Eloranta J, Rogler G, and Rui P
- Subjects
Inflammation ,TDAG8 ,Inflammatory Bowel Disease ,GRP65 ,Ovarian Cancer G-Protein-Coupled Receptor - Abstract
BACKGROUND & AIMS: A novel family of proton-sensing G-protein-coupled receptors, including ovarian cancer G-protein-coupled receptor 1 (OGR1) (GPR68) has been identified to play a role in pH homeostasis. Hypoxia is known to change tissue pH as a result of anaerobic glucose metabolism through the stabilization of hypoxia-inducible factor-1 alpha. We investigated how hypoxia regulates the expression of OGR1 in the intestinal mucosa and associated cells. METHODS: OGR1 expression in murine tumors, human colonic tissue, and myeloid cells was determined by quantitative reverse-transcription polymerase chain reaction. The influence of hypoxia on OGR1 expression was studied in monocytes/macrophages and intestinal mucosa of inflammatory bowel disease (IBD) patients. Changes in OGR1 expression in MonoMac6 (MM6) cells under hypoxia were determined upon stimulation with tumor necrosis factor (TNF), in the presence or absence of nuclear factor-kappa B (NF-kappa B) inhibitors. To study the molecular mechanisms involved, chromatin immunoprecipitation analysis of the OGR1 promoter was performed. RESULTS: OGR1 expression was significantly higher in tumor tissue compared with normal murine colon tissue. Hypoxia positively regulated the expression of OGR1 in MM6 cells, mouse peritoneal macrophages, primary human intestinal macrophages, and colonic tissue from IBD patients. In MM6 cells, hypoxia-enhanced TNF-induced OGR1 expression was reversed by inhibition of NF-kappa B. In addition to the effect of TNF and hypoxia, OGR1 expression was increased further at low pH. Chromatin immunoprecipitation analysis showed that HIF-1 alpha, but not NF-kappa B, binds to the promoter of OGR1 under hypoxia. CONCLUSIONS: The enhancement of TNF- and hypoxia-induced OGR1 expression under low pH points to a positive feed-forward regulation of OGR1 activity in acidic conditions, and supports a role for OGR1 in the pathogenesis of IBD.
- Published
- 2016
10. Nevus comedonicus with lesional growth of terminal hair: An unusual case.
- Author
-
Juratli HA, Madanchi M, Curatolo R, Didona D, and Happle R
- Published
- 2024
- Full Text
- View/download PDF
11. Ultra-high Potency Topical Corticosteroids as a Potential Trigger for Reactive Perforating Collagenosis.
- Author
-
Madanchi M, Curatolo R, Juratli HA, Mangas C, and Mainetti C
- Subjects
- Humans, Middle Aged, Administration, Cutaneous, Adrenal Cortex Hormones administration & dosage, Adrenal Cortex Hormones adverse effects, Glucocorticoids administration & dosage, Glucocorticoids adverse effects, Treatment Outcome, Collagen Diseases chemically induced, Collagen Diseases drug therapy, Collagen Diseases pathology
- Published
- 2024
- Full Text
- View/download PDF
12. Anti-p200 Pemphigoid.
- Author
-
Madanchi M and Pelloni LS
- Abstract
Competing Interests: The authors have no conflicts of interest regarding this article, and have received no funding for this work.
- Published
- 2024
- Full Text
- View/download PDF
13. Fluoroscopy-only guided transcatheter patent foramen ovale closure: the importance of pre-procedural echocardiography.
- Author
-
Wolfrum M, Moccetti F, Conrad N, Loretz L, Madanchi M, Bossard M, Attiger-Toller A, Cuculi F, Stämpfli SF, and Toggweiler S
- Abstract
Objectives: Percutaneous closure of a patent foramen ovale (PFO) to prevent recurrent paradoxical thromboembolic events has become the standard of care. However, it remains uncertain if transesophageal echocardiography (TOE) guidance improves procedural success with an existing comprehensive pre-procedural TOE. The aim of the study was to compare the effectiveness of percutaneous PFO closure guided by fluoroscopy (FS) only vs TOE plus FS., Methods: Consecutive patients undergoing percutaneous PFO closure between February 2017 and April 2023 were analyzed. Based on pre-procedural echocardiography, patients were scheduled either for an FS-only or TOE/FS-guided procedure. The primary-endpoint was effective PFO-closure (residual-shunt grade 0/1 at 6-month follow-up). The secondary-endpoints included procedural safety/efficacy and major adverse cardiovascular events during hospital stay and at the 6-month follow-up., Results: Two hundred-three patients (mean age 51.8 ± 12.5 years, 39.4% women, Risk of Paradoxical Embolism score = 7 [IQR = 6-7]) underwent PFO closure with FS-only guidance (88 patients, 43.3%) or TOE/FS guidance (115 patients, 56.7%). The main indications for PFO closure were cryptogenic stroke (179 patients, 88.2%) and peripheral embolism (13 patients, 6.4%). At baseline, a right-to-left shunt of grade 2 or higher was present in 199 patients (98%). The procedure time in the FS group was shorter (13 minutes in the FS group vs 16.5 minutes in the TOE/FS group, P = .002). The immediate procedural success was 99.5%. At 6 months, effective closure was achieved in 195 patients (96.1% [FS group: 97.7% vs TOE/FS group 97.8%, P = .29]). The rates of atrial fibrillation and recurrent thromboembolic events were not different among the procedural strategies (3.9% [P = .47] and 0.5% [P = .43])., Conclusions: After comprehensive pre-procedural echocardiography workup, PFO closure with FS guidance only seems equally safe and effective as TOE/FS guidance. A standardized pre-procedural echocardiography protocol facilitates procedural planning with excellent echocardiographic and clinical outcomes.
- Published
- 2024
- Full Text
- View/download PDF
14. The periscope sign as a new dermatoscopy finding to facilitate the diagnosis of furuncular myiasis.
- Author
-
Madanchi M, Merkel T, Juratli HA, and Curatolo R
- Subjects
- Humans, Animals, Male, Travel, Female, Myiasis diagnosis, Dermoscopy methods
- Published
- 2024
- Full Text
- View/download PDF
15. Deep Trichophytosis Mimiking Superinfected Bacterial Folliculitis.
- Author
-
Weiss L, Cerminara SE, Curatolo R, Juratli HA, and Madanchi M
- Subjects
- Humans, Tinea microbiology, Tinea diagnosis, Tinea pathology, Male, Female, Folliculitis microbiology, Folliculitis diagnosis, Folliculitis pathology
- Published
- 2024
- Full Text
- View/download PDF
16. Initial experience with a novel stent-based mechanical thrombectomy device for management of acute myocardial infarction cases with large thrombus burden.
- Author
-
Zhi Y, Madanchi M, Cioffi GM, Brunner J, Stutz L, Gnan E, Gjergjizi V, Attinger-Toller A, Cuculi F, and Bossard M
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Prospective Studies, Treatment Outcome, Coronary Thrombosis surgery, Coronary Thrombosis therapy, Registries, Percutaneous Coronary Intervention methods, Coronary Angiography, Aged, 80 and over, Thrombectomy methods, Thrombectomy instrumentation, Myocardial Infarction surgery, Stents
- Abstract
Background: Patients with acute myocardial infarction (AMI) and large thrombus burden (LTB) still represent a challenge. Afflicted patients have a high morbidity and mortality. Aspiration thrombectomy is often ineffective in those cases. Mechanical thrombectomy devices (MTDs), which are effective for management of ischemic strokes, were recently CE-approved for treatment of thrombotic coronary lesions. Real-world data about their performance in AMI cases with LTB are scarce. This study sought to summarize our early experience with a novel MTD device in this context., Methods: We analyzed consecutive patients from the prospective OPTIMISER registry (NCT04988672), who have been managed with the NeVa™ MTD (Vesalio, USA) for AMI with LTB at a tertiary cardiology facility. Outcomes of interest included, among others, periprocedural complications, target lesion failure (TLF), target lesion revascularization (TLR) and target vessel myocardial infarction (TV-MI)., Results: Overall, 15 patients underwent thrombectomy with the NeVa™ device. Thrombectomy was successfully performed in 14 (93%) patients. Final TIMI 3 flow was achieved in 13 (87%) patients, while 2 (13%) patients had TIMI 2 flow. We encountered no relevant periprocedural complications, especially no stroke, stent thrombosis or vessel closure. After a mean follow-up time of 26 ± 2.9 months, 1 (7%) patient presented with TLR due to stent thrombosis (10 months after treatment with the MTD and stenting)., Conclusions: In AMI patients with LTB, the deployment of the novel NeVa™ MTD seems efficient and safe. Further randomized trials are warranted to assess whether the use of the NeVa™ device in cases with LTB improves procedural and clinical outcomes., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. The impact of colchicine on patients with acute and chronic coronary artery disease.
- Author
-
Madanchi M, Young M, Tersalvi G, Maria Cioffi G, Attinger-Toller A, Cuculi F, Kurmann R, and Bossard M
- Subjects
- Humans, Randomized Controlled Trials as Topic, Chronic Disease, Inflammation drug therapy, Myocardial Infarction drug therapy, Acute Disease, Colchicine therapeutic use, Colchicine adverse effects, Coronary Artery Disease drug therapy, Anti-Inflammatory Agents therapeutic use, Anti-Inflammatory Agents adverse effects
- Abstract
Inflammation plays a central role in coronary artery disease (CAD), and recent data have shown that anti-inflammatory drugs have the potential to reduce ischemic events in CAD patients. Colchicine is an ancient anti-inflammatory drug that targets neutrophil and inflammasome activities. It has been prescribed for decades for different rheumatological conditions. Given the important role of inflammation in the development of cardiovascular disease, there has been considerable interest in studying colchicine's potential to limit the progression of atherosclerosis among afflicted patients. In fact, there is a growing body of randomized data suggesting that use of low-dose colchicine reduces the risk of ischemic events in patients with CAD, particularly repeated revascularizations, new myocardial infarctions and strokes. This review article summarizes background information-including possible side effects and contraindications-as well as the current evidence backing up the use of colchicine in patients with established CAD., Competing Interests: Conflicts of interest No external funding was used to support this work. M.B. receives consulting and speaker fees from Abbott Vascular, Abiomed, Astra Zeneca, Amgen, Bayer, Boehringer Ingelheim, Daichii Sankyo, Mundipharma, Novo Nordisk, Novartis, SIS Medical, as well as travel grants from Pfizer and Vifor SA. None of the other authors have any relevant conflicts to declare., (Copyright © 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Slow-growing painful verrucous nodule on finger.
- Author
-
Madanchi M, Curatolo R, Mühleisen B, and Juratli HA
- Published
- 2024
- Full Text
- View/download PDF
19. Delayed-type hypersensitivity reaction to jellyfish.
- Author
-
Curatolo R, Madanchi M, and Juratli HA
- Subjects
- Animals, Humans, Cnidarian Venoms adverse effects, Scyphozoa immunology, Hypersensitivity, Delayed diagnosis, Hypersensitivity, Delayed immunology, Hypersensitivity, Delayed etiology
- Published
- 2024
- Full Text
- View/download PDF
20. Lymphatic Filariasis.
- Author
-
Madanchi M and Itin P
- Subjects
- Animals, Humans, Male, Aged, Treatment Outcome, Doxycycline therapeutic use, Albendazole administration & dosage, Albendazole therapeutic use, Diethylcarbamazine administration & dosage, Diethylcarbamazine therapeutic use, Edema etiology, Edema parasitology, Penis, Scrotum, Leg, Magnetic Resonance Imaging, Elephantiasis, Filarial complications, Elephantiasis, Filarial diagnosis, Elephantiasis, Filarial drug therapy, Filaricides administration & dosage, Filaricides therapeutic use, Wuchereria bancrofti isolation & purification
- Published
- 2024
- Full Text
- View/download PDF
21. Amplatzer or Figulla Flex II Occluder: a comparative study of outcomes after transcatheter patent foramen ovale closure.
- Author
-
Toggweiler S, Moccetti F, Conrad N, Loretz L, Madanchi M, Bossard M, Attiger-Toller A, Cuculi F, and Wolfrum M
- Subjects
- Humans, Female, Adult, Middle Aged, Male, Treatment Outcome, Echocardiography, Cardiac Catheterization methods, Foramen Ovale, Patent diagnosis, Foramen Ovale, Patent surgery, Foramen Ovale, Patent complications, Stroke epidemiology, Stroke etiology, Stroke prevention & control, Septal Occluder Device adverse effects, Thromboembolism etiology
- Abstract
Objectives: Percutaneous closure of a patent foramen ovale (PFO) for the prevention of recurrent paradoxical thromboembolic events has been shown to be safe and effective in randomized controlled trials. However, it remains uncertain if differences in the structure and design of the occluder devices impact the outcomes. The aim of this study was to compare results of percutaneous PFO closure using 2 widely used double-disc occluders., Methods: Consecutive patients who underwent percutaneous PFO closure with the Abbott Amplatzer occluder (APO) or the Occlutech Figulla-Flex-II occluder (OPO) at the Heart Center Lucerne between February 2017 and December 2022 were included in a registry. The primary endpoint was effective closure of the PFO, defined as a residual shunt grade 0 or 1, assessed by contrast echocardiogram at 6-month follow-up. Secondary endpoints included procedural efficacy/safety and major adverse cardiovascular events during the hospital stay and at 6-month follow-up., Results: One hundred ninety-three consecutive patients (mean age 51.7 ± 12.5 years; 39% women; Risk of Paradoxical Embolism (RoPE) score = 7, IQR = 6-8) underwent percutaneous PFO closure with the APO (120 patients, 62.2%) or the OPO (73 patients, 37.8%). Main indications for closure were crypotogenic stroke in 168 patients (87.1%) and peripheral embolism in 13 patients (6.7%). At baseline, right-to-left shunt (RLS) greater than or equal to grade 2 was present in 189 patients (97.9%). Immediate procedural success was 99.5%. In 1 patient, an air embolism occurred during positioning of the APO occluder with transient chest pain and electrocardiogram changes, but without further sequelae to the patient. At 6-month follow-up, effective closure was achieved in 185 patients (95.8%; APO: 96.6% vs OPO: 94.5%, P = .30). Rates of atrial fibrillation and recurrent thromboembolic events were 4.2 and 0.5%, respectively., Conclusions: PFO closure is safe and effective when performed with either the self-expanding Abbott Amplatzer or Occlutech Figulla Flex II PFO occluder.
- Published
- 2024
- Full Text
- View/download PDF
22. Outcomes following coronary chronic total occlusion revascularization with drug-coated balloons.
- Author
-
Madanchi M, Bossard M, Majcen I, Cioffi GM, Ferraro F, Gnan E, Gjergjizi V, Zhi Y, Bade V, Wolfrum M, Moccetti F, Toggweiler S, Attinger-Toller A, and Cuculi F
- Subjects
- Humans, Prospective Studies, Heart, Coronary Vessels diagnostic imaging, Coronary Vessels surgery, Coronary Occlusion diagnosis, Coronary Occlusion surgery, Percutaneous Coronary Intervention adverse effects, Chlorobenzenes
- Abstract
Objectives: Despite the introduction of improved drug eluting stents (DES), the rate of repeat revascularization procedures following percutaneous coronary interventions (PCI) in coronary chronic total occlusions (CTO) remains high. By leaving vessels uncaged and limiting length of stented segments, drug-coated balloons (DCB) represent an appealing alternative to DES for CTO-PCI. Since data supporting the use of DCBs in CTO-PCI is scarce, we compared the outcomes of patients undergoing CTO-PCI involving DCBs vs DES only., Methods: From 2 prospective registries, outcomes of patients undergoing CTO-PCI involving DCBs and those undergoing PCI with DES only were compared. Outcomes included major adverse cardiac and cerebrovascular events (MACCE) and cardiovascular death (CV-death)., Results: Overall, 157 patients were studied; 112 (71%) underwent CTO-PCI involving DCBs and 45 (29%) were treated with DES only. Mean J-CTO score was 1.84 ± 0.7. Most CTO-lesions involved the right coronary artery, 88 (56%), and 26 (17%) cases were in-stent occlusions. In the DCB group, 46 (41%) lesions were treated with DCBs alone. Mean lengths of the stented segments in the DCB vs DES cohorts were 59 ± 28 mm vs 87 ± 37 mm (P less than .001), respectively. After 12 months, the MACCE rate was higher in the DES only vs DCB group (26% vs 11%, P=.03). Length of the stented segment was an independent predictor for MACCE (HR 1.15 [95% CI, 1.05-1.26] per 10-mm stent length)., Conclusions: Revascularization of CTO lesions involving DCBs appears safe and potentially lowers MACCE rates compared to treatment with DES alone. Importantly, using DCBs for CTO treatment may reduce total stent length, which determines PCI outcomes.
- Published
- 2024
- Full Text
- View/download PDF
23. Treatment of coronary lesions with a novel crystalline sirolimus-coated balloon.
- Author
-
Madanchi M, Attinger-Toller A, Gjergjizi V, Majcen I, Cioffi GM, Epper A, Gnan E, Koch T, Zhi Y, Cuculi F, and Bossard M
- Abstract
Background: There is mounting data supporting the use of drug-coated balloons (DCB) not only for treatment of in-stent restenosis (ISR), but also in native coronary artery disease. So far, paclitaxel-coated balloons represented the mainstay DCBs. The SeQuent® crystalline sirolimus-coated balloon (SCB) (B.Braun Medical Inc, Germany) represents a novel DCB, which allows a sustained release of the limus-drug. We evaluated its performance in an all-comer cohort, including complex coronary lesions., Methods: Consecutive patients treated with the SeQuent® SCB were analyzed from the prospective SIROOP registry (NCT04988685). We assessed clinical outcomes, including major adverse cardiovascular events (MACE), target lesion revascularization (TLR), target vessel myocardial infarction (TV-MI) and cardiovascular death. Angiograms and outcomes were independently adjudicated., Results: From March 2021 to March 2023, we enrolled 126 patients and lesions, of which 100 (79%) treated using a "DCB-only" strategy and 26 (21%) with a hybrid approach (DES + DCB). The mean age was 68 ± 10 years, 48 (38%) patients had an acute coronary syndrome. Regarding lesion characteristics, ISR was treated in 27 (21%), 11 (9%) underwent CTO-PCI and 59 (47%) of the vessels were moderate to severe calcified. Procedural success rate was 100%. At a median follow-up time of 12.7 (IQR 12; 14.2) months, MACE occurred in 5 patients (4.3%). No acute vessel closure was observed., Conclusions: Our data indicates promising outcomes following treatment with this novel crystalline SCB in an all-comer cohort with complex coronary lesions. These results require further investigation with randomized trials., Competing Interests: AA-T has received consulting and speaker fees from SIS Medical. MB has received consulting and speaker fees from Abbott Vascular, Abiomed, Amarin, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Daichii, MedAlliance, Mundipharma, Novartis, OmPharma and SIS Medical. FC has received consulting and speaker fees from Abbott Vascular, Abiomed, Boston Scientific and SIS Medical. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2024 Madanchi, Attinger-Toller, Gjergjizi, Majcen, Cioffi, Epper, Gnan, Koch, Zhi, Cuculi and Bossard.)
- Published
- 2024
- Full Text
- View/download PDF
24. The Pink Doughnut Sign-A Clinical Clue to Recognize Basal Cell Carcinoma Presenting as Chronic Leg Ulcer.
- Author
-
Madanchi M, Müller A, Zehnder ML, and Müller SM
- Abstract
Chronic lower leg ulcers (LLUs) are a very common and associated with a high subjective and economic burden. They can be caused by a variety of factors. We have observed a common clinical feature in patients suffering from LLUs, which ultimately proved to be basal cell carcinomas (BCCs). We have nicknamed this sign "the pink doughnut sign." The pink doughnut sign can aid in the early recognition of such BCCs, which is crucial to prevent unnecessary suffering, treatment costs, and poor local outcomes., Competing Interests: Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2023
- Full Text
- View/download PDF
25. Mitigating the risk of flow deterioration by deferring stent optimization in STEMI patients with large thrombus burden: Insights from a prospective cohort study.
- Author
-
Cioffi GM, Zhi Y, Madanchi M, Seiler T, Stutz L, Gjergjizi V, Romero JP, Attinger-Toller A, Bossard M, and Cuculi F
- Subjects
- Female, Humans, Male, Prospective Studies, Treatment Outcome, Stents, Coronary Angiography methods, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction therapy, ST Elevation Myocardial Infarction etiology, Coronary Thrombosis diagnostic imaging, Coronary Thrombosis etiology, Coronary Thrombosis therapy, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention methods
- Abstract
Objectives: It is uncertain, if omitting post-dilatation and stent oversizing (stent optimization) is safe and may decrease the risk for distal thrombus embolization (DTE) in STEMI patients with large thrombus burden (LTB)., Background: In patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) with stenting, (DTE) and flow deterioration are common and increase infarct size leading to worse outcomes., Methods: From a prospective registry, 74 consecutive STEMI patients with LTB undergoing pPCI with stenting and intentionally deferred stent optimization were analyzed. Imaging data and outcomes up to 2 years follow-up were analyzed., Results: Overall, 74 patients (18% females) underwent deferred stent optimization. Direct stenting was performed in 13 (18%) patients. No major complications occurred during pPCI. Staged stent optimization was performed after a median of 4 (interquartile range (IQR) 3; 7) days. On optical coherence tomography, under-expansion and residual thrombus were present in 59 (80%) and 27 (36%) cases, respectively. During deferred stent optimization, we encountered no case of flow deterioration (slow or no-reflow) or side branch occlusion. Minimal lumen area (mm
2 ) and stent expansion (%) were corrected from 4.87±1.86mm to 6.82±2.36mm (p<0.05) and from 69±18% to 91±12% (p<0.001), respectively. During follow-up, 1 patient (1.4%) required target lesion revascularization and 1 (1.4%) patient succumbed from cardiovascular death., Conclusions: Among STEMI patients with LTB, deferring stent optimization in the setting of pPCI appears safe and potentially mitigates the risk of DTE. The impact of this approach on infarct size and clinical outcomes warrants further investigation in a dedicated trial., (© 2023. BioMed Central Ltd., part of Springer Nature.)- Published
- 2023
- Full Text
- View/download PDF
26. Painless Red Nodule on the Right Cheek of a Young Woman: A Quiz.
- Author
-
Madanchi M, Quoss MK, and Mühleisen B
- Subjects
- Female, Humans, Cheek pathology
- Published
- 2023
- Full Text
- View/download PDF
27. Ageusie als Symptom bei Affenpockeninfektion.
- Author
-
Madanchi M, Brenner M, Navarini AA, and Juratli HA
- Published
- 2023
- Full Text
- View/download PDF
28. Ageusia as a symptom of monkeypox infection.
- Author
-
Madanchi M, Brenner M, Navarini AA, and Juratli HA
- Subjects
- Humans, Ageusia, Mpox (monkeypox)
- Published
- 2023
- Full Text
- View/download PDF
29. Treatment of Calcified Lesions Using a Dedicated Super-High Pressure Balloon: Multicenter Optical Coherence Tomography Registry.
- Author
-
Pinilla-Echeverri N, Bossard M, Hillani A, Chavarria JA, Cioffi GM, Dutra G, Guerrero F, Madanchi M, Attinger A, Kossmann E, Sibbald M, Cuculi F, and Sheth T
- Subjects
- Humans, Tomography, Optical Coherence, Retrospective Studies, Calcium, Treatment Outcome, Stents, Registries, Coronary Angiography methods, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Coronary Artery Disease etiology, Angioplasty, Balloon, Coronary, Vascular Calcification diagnostic imaging, Vascular Calcification therapy, Vascular Calcification etiology
- Abstract
Background: Calcified lesions often lead to difficulty achieving optimal stent expansion. OPN non-compliant (NC) is a twin layer balloon with high rated burst pressure that may modify calcium effectively., Methods: Retrospective, multicenter registry in patients undergoing optical coherence tomography (OCT) guided intervention with OPN NC. Superficial calcification with > 180
o arc and > 0.5 mm thickness, and/or nodular calcification with > 90o arc were included. OCT was performed in all cases before and after OPN NC, and after intervention. Primary efficacy endpoints were frequency of expansion (EXP) ≥80 % of the mean reference lumen area and mean final EXP by OCT, and secondary endpoints were calcium fractures (CF), and EXP ≥90 %., Results: 50 cases were included; 25 (50 %) superficial, and 25 (50 %) nodular. Calcium score of 4 in 42 (84 %) cases and 3 in 8 (16 %). OPN NC was used alone, or after other devices if further modification was needed, NC in 27 (54 %), cutting in 29 (58 %), scoring in 1 (2 %), IVL in 2 (4 %); or if non-crossable lesion, rotablation in 5 (10 %) cases. EXP ≥80 % was achieved in 40 (80 %) cases with mean final EXP post intervention of 85.7 % ± 8.9. CF were documented in 49 (98 %) cases; multiple in 37 (74 %). There were 1 flow limiting dissection requiring stent deployment and 3 non-cardiovascular related deaths in 6 months follow-up. No records of perforation, no-reflow or other major adverse events., Conclusion: Among patients with heavy calcified lesions undergoing OCT guided intervention with OPN NC, acceptable expansion was achieved in most cases without procedure related complications., Competing Interests: Declaration of competing interest Authors have the following disclosures relevant to this manuscript: The OPN NC Registry was supported by an AFP grant through Hamilton Health Sciences. Dr. Pinilla-Echeverri has served as a consultant and speaker, received research grant support, and served on the Advisory Board for Abbott Vascular; has served on the Advisory Board for Philips; has served as a consultant for Conavi, Amgen, Bayer, and Novartis. Dr. Bossard has served as consultant and speaker fees for Abbott Vascular, Abiomed, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Dachii Sankyo, Novartis, SIS Medical and Vifor. Dr. Chavarria has served as a consultant and speaker for Abbott Vascular. Dr. Dutra has served as a consultant for Abbott Vascular. Dr. Attinger has served as a speaker for SIS Medical. Dr. Sibbald has served as a consultant for Abbott Vascular. Dr. Cuculi has received consulting and speaker fees from Abiomed, Boston Scientific, SIS Medical and Abbott Vascular. Dr. Sheth has served as a consultant, served on the Speakers Bureau, received research grant support, and served on the Advisory Board for Abbott Vascular. Dr. Hillani, Dr. Cioffi, Dr. Guerrero, Dr. Madanchi and Ellen Kossmann have nothing to disclose., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
30. Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Treatment of Left Ventricular Thrombi-Insights from a Swiss Multicenter Registry.
- Author
-
Seiler T, Vasiliauskaite E, Grüter D, Young M, Attinger-Toller A, Madanchi M, Cioffi GM, Tersalvi G, Müller G, Stämpfli SF, de Boeck B, Suter Y, Nossen J, Toggweiler S, Wuillemin WA, Cuculi F, Kobza R, and Bossard M
- Subjects
- Humans, Female, Middle Aged, Aged, Male, Stroke Volume, Switzerland, Ventricular Function, Left, Anticoagulants therapeutic use, Fibrinolytic Agents therapeutic use, Vitamin K, Registries, Administration, Oral, Thrombosis drug therapy, Thromboembolism drug therapy
- Abstract
Current guidelines recommend vitamin K antagonists (VKAs) for the treatment of a left ventricular thrombus (LVT). However, direct oral anticoagulants (DOACs) show superior safety and efficacy compared with VKAs in most thromboembolic disorders. Nevertheless, DOACs remain poorly investigated for the treatment of LVT. To describe the thrombus resolution rate and clinical efficacy of DOACs versus VKAs in patients with LVT, we analyzed consecutive patients with confirmed LVT from a multicenter echocardiography database. Echocardiograms and clinical end points were evaluated independently. The thrombus resolution rate and clinical outcomes were compared according to the underlying anticoagulation regimen. In total, 101 patients were included (17.8% women, mean age 63.3 ± 13.2 years), 50.5% had recently experienced a myocardial infarction. The mean left ventricular ejection fraction was 36.6 ± 12.2%. DOACs versus VKAs were used in 48 and 53 patients, respectively. The median follow-up was 26.6 (interquartile range 11.8;41.2) months. Among patients receiving VKAs compared with DOACs, the thrombus resolved more rapidly within the first month in those taking VKAs (p = 0.049). No differences were seen between the 2 groups with respect to major bleedings, strokes, and other thromboembolic events. In each group, LVT recurred in 3 of the subjects (a total of 6) after discontinuation of anticoagulation. In conclusion, DOACs appear to be a safe and effective alternative to VKAs for the treatment of LVTs, but the rate of thrombus dissolution within 1 month after initiation of anticoagulation appears to be higher with VKAs. A sufficiently powered randomized trial is required to definitively define the role of DOACs in the treatment of LVT., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
31. Ignatzschineria larvae Bacteremia in a Patient With Chronic Leg Ulcer: A Case Report and Review of the Literature.
- Author
-
Demurtas S, Pareti E, and Madanchi M
- Abstract
Ignatzschineria larvae ( I. larvae ) is a bacterium found in the digestive tract of some flies. A few cases of bacteremia by I. larvae are described in the literature. We present the case of a patient with chronic leg ulcer and poor hygienic and social conditions, who presented with bacteremia from I. larvae . As there are few cases described in the literature, there are no guidelines yet for the treatment of this bacteremia. We report a short review of the literature below., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2023, Demurtas et al.)
- Published
- 2023
- Full Text
- View/download PDF
32. Treatment of In-Stent Restenosis Using a Dedicated Super High-Pressure Balloon.
- Author
-
Seiler T, Attinger-Toller A, Cioffi GM, Madanchi M, Teufer M, Wolfrum M, Moccetti F, Toggweiler S, Kobza R, Bossard M, and Cuculi F
- Subjects
- Male, Humans, Middle Aged, Aged, Aged, 80 and over, Female, Stents adverse effects, Switzerland, Treatment Outcome, Coronary Angiography adverse effects, Angioplasty, Balloon, Coronary adverse effects, Coronary Restenosis diagnostic imaging, Coronary Restenosis etiology, Coronary Restenosis therapy, Percutaneous Coronary Intervention adverse effects
- Abstract
Background: Treatment of in-stent restenosis (ISR) is challenging and treatment failure rate remains high. Correction of stent under-expansion and neointimal compression using the twin-layer OPN™ highly non-compliant balloon (NCB) at high pressure (>30 atm) may lead to increased luminal gain and thus better clinical outcomes. We evaluated periprocedural safety and clinical long-term outcomes after ISR treatment using the OPN™ NCB in a real-world population., Methods: From an ongoing registry, consecutive ISR patients treated with the OPN™ NCB at a tertiary cardiology center in Switzerland were analyzed. We evaluated procedural efficacy, periprocedural complications, target lesion/vessel failure (TLF/TVF), and major adverse cardiovascular events (MACE)., Results: Totally, 208 ISR lesions were treated in 188 patients (mean age 68 ± 13 years, 78 % males). Most lesions were moderately to heavily calcified (89 %), the majority (70.2 %) had complex lesion characteristics (AHA Type B2/C lesions) and 50.5 % were non-focal ISR lesions. After ISR treatment using high pressure pre- and post-dilatation (mean pressure 33 ± 6 atm) with the OPN™ NCB device, the rate of major complications was low (0.96 % coronary perforation, 4 % major dissections, 1.9 % no-reflow and 0.5 % acute vessel closure). At 1-year follow-up, MACE occurred in 19.7 %; 15.4 % patients had TVF; MI and stent thrombosis was found in 5.9 % and 2.1 % of all patients, respectively; and 5 patients died., Conclusions: For ISR treatment, using the super non-compliant OPN™ balloon at very high pressures is safe. Moreover, its use might lead to a low rate of TLF/TVF during long-term follow-up, but this requires further evaluation in dedicated comparative trials., Competing Interests: Declaration of competing interest AAT has received consulting and speaker fees from SIS Medical. RK has received institutional grants from Abbott, Biosense-Webster, Biotronik, Boston-Scientific, Medtronic, SIS Medical and act as a consultant for Biosense-Webster, Biotronik and Medtronic. MB has received consulting and speaker fees from Abbott Vascular, Abiomed and SIS Medical. FC has received consulting and speaker fees from SIS Medical, Abiomed and Abbott Vascular. All other authors have no conflicts of interest to declare., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
33. Trajectories of Cardiac Function Following Treatment With an Impella Device in Patients With Acute Anterior ST-Elevation Myocardial Infarction.
- Author
-
Tersalvi G, Attinger-Toller A, Kalathil D, Winterton D, Cioffi GM, Madanchi M, Seiler T, Stadelmann M, Goffredo F, Fankhauser P, Moccetti F, Wolfrum M, Toggweiler S, Bloch A, Kobza R, Cuculi F, and Bossard M
- Abstract
Background: Left ventricular (LV) unloading via the percutaneous micro-axial Impella pump is increasingly used in patients with anterior ST-segment elevation myocardial infarction (STEMI) and overt cardiogenic shock. In this context, the evolution of cardiac function and dimensions beyond hospital discharge remains uncertain. We aimed to characterize echocardiographic changes over time in patients with acute anterior STEMI treated with an Impella device., Methods: From an ongoing prospective registry, consecutive patients with acute anterior STEMI managed with an Impella device were extracted. Transthoracic echocardiography was performed at index hospitalization and at first outpatient follow-up. Predictors of response, defined as a ≥ 10% absolute increase in left ventricular ejection fraction (LVEF) at follow-up, were sought., Results: A total of 66 patients (89.4% male, aged 64.3 ± 11.6 years) with anterior STEMI were treated with an Impella device in the first 24 hours of hospitalization, from 2014 to 2022. In-hospital mortality was 24%. Major bleeding and vascular complications requiring surgery occurred in 24% and 11% of patients, respectively. At baseline, mean LVEF was 34% ±12%. At follow-up, survivors showed a significant increase in LVEF ( P < 0.0001), whereas LV dimensions, diastolic parameters, and measures of right ventricular dimension and function remained stable. Overall, 28 patients had a ≥ 10% absolute increase in LVEF at follow-up. Baseline creatinine was the only significant predictor of response at univariate analysis., Conclusions: Among patients with anterior STEMI requiring mechanical hemodynamic support with an Impella device, the majority of survivors showed a sustained increase in LV function, without evidence of adverse remodelling. This signal warrants further investigation in dedicated trials., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
34. Pushing the Boundaries: Drug-Coated Balloons to Treat a Calcified and Thrombotic Lesion in Acute Coronary Syndrome.
- Author
-
Cioffi GM, Madanchi M, Attinger-Toller A, Bossard M, and Cuculi F
- Subjects
- Aged, Coronary Angiography methods, Humans, Male, Sirolimus, Treatment Outcome, Acute Coronary Syndrome diagnostic imaging, Acute Coronary Syndrome therapy, Angioplasty, Balloon, Coronary methods, Coronary Artery Disease therapy, Coronary Restenosis, Percutaneous Coronary Intervention
- Abstract
BACKGROUND Use of drug-coated balloons (DCB) is an important research topic. Many companies are quickly developing new, cutting-edge technologies and means to deliver drugs. Moreover, interest is growing in use of sirolimus-coated balloons, a promising technology in the "leaving nothing behind" era. This, in combination with interest in lesion preparation and intravascular imaging, creates a promising future for DCB for years to come. CASE REPORT A 72-year-old patient presented with NSTEMI. Coronary angiography showed a subtotal stenosis of the right coronary artery (RCA). PCI was performed on the native RCA and, given the patient's failure to adhere to the drug regimen, he was treated with a metal-free PCI strategy. After using a novel lesion preparation technique with cutting balloon and high-pressure non-compliant balloon, a novel Sirolimus DCB was used. Final angiography and OCT run showed good luminal gain despite diffuse dissections. To assess vascular healing, we performed coronary angiography 5 weeks later, which demonstrated an excellent result, with absence of residual dissection and further luminal gain compared to the index procedure. CONCLUSIONS The use of a novel lesion preparation technique (cutting balloon and high-pressure highly non-compliant balloon) in combination with guidance by intravascular imaging and the use of a new sirolimus-coated balloon may attract attention in the interventional cardiology community and stimulate discussion on lesion preparation and use of drug-coated balloons.
- Published
- 2022
- Full Text
- View/download PDF
35. Manual compression versus MANTA device for access management after impella removal on the ICU.
- Author
-
Cuculi F, Burkart P, Cioffi G, Moccetti F, Madanchi M, Seiler T, Hess S, Wolfrum M, Jeyarasa M, Meier S, Kuzmiakova S, Hakimi M, Seelos R, Kobza R, Toggweiler S, Attinger-Toller A, and Bossard M
- Subjects
- Aged, Femoral Artery surgery, Hemorrhage etiology, Hemorrhage therapy, Humans, Intensive Care Units, Middle Aged, Treatment Outcome, Transcatheter Aortic Valve Replacement adverse effects, Vascular Closure Devices adverse effects
- Abstract
To compare the safety and efficacy of manual compression versus use of the MANTA closure device for access management after Impella removal on the intensive care unit (ICU). The number of patients treated with percutaneous left ventricular assist devices (pLVAD), namely Impella and ECMO, for complex cardiac procedures or shock, is growing. However, removal of pLVAD and large bore arteriotomy closure among such patients on the ICU remains challenging, since it is associated with a high risk for bleeding and vascular complications. Patients included in a prospective registry between 2017 and 2020 were analyzed. Bleeding and vascular access site complications were assessed and adjudicated according to VARC-2 criteria. We analyzed a cohort of 87 consecutive patients, who underwent access closure after Impella removal on ICU by using either the MANTA device or manual compression. The cohort´s mean age was 66.1 ± 10.7 years and 76 patients (87%) were recovering from CS. Mean support time was 40 h (interquartile range 24-69 h). MANTA was used in 31 patients (35.6%) and manual compression was applied in 56 patients (64.4%). Overall access related bleedings were significantly lower in the MANTA group (6.5% versus 39.3% (odds ratio (OR) 0.10, 95% CI 0.01-0.50; p = 0.001), and there was no significant difference in vascular complications between the two groups (p = 0.55). Our data suggests that the application of the MANTA device directly on the ICU is safe. In addition, it seems to reduce access related bleeding without increasing the risk of vascular complications., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
36. Long-Term Outcomes After Implantation of Magnesium-Based Bioresorbable Scaffolds-Insights From an All-Comer Registry.
- Author
-
Bossard M, Madanchi M, Avdijaj D, Attinger-Toller A, Cioffi GM, Seiler T, Tersalvi G, Kobza R, Schüpfer G, and Cuculi F
- Abstract
Background: The magnesium-based sirolimus-eluting bioresorbable scaffold (Mg-BRS) Magmaris™ showed promising clinical outcomes, including low rates of both the target lesion failure (TLF) and scaffold thrombosis (ScT), in selected study patients. However, insights regarding long-term outcomes (>2 years) in all-comer populations remain scarce., Methods: We analyzed data from a single-center registry, including patients with acute coronary syndrome (ACS) and chronic coronary syndrome (CCS), who had undergone percutaneous coronary intervention (PCI) using the Mg-BRS. The primary outcome comprised the device-oriented composite endpoint (DoCE) representing a hierarchical composite of cardiac death, ScT, target vessel myocardial infarction (TV-MI), and clinically driven target lesion revascularization (TLR) up to 5 years., Results: In total, 84 patients [mean age 62 ± 11 years and 63 (75%) men] were treated with the Mg-BRS devices between June 2016 and March 2017. Overall, 101 lesions had successfully been treated with the Mg-BRS devices using 1.2 ± 0.4 devices per lesion. Pre- and postdilatation using dedicated devices had been performed in 101 (100%) and 98 (97%) of all the cases, respectively. After a median follow-up time of 62 (61-64) months, 14 (18%) patients had experienced DoCEs, whereas ScT was encountered in 4 (4.9%) patients [early ScTs (<30 days) in three cases and two fatal cases]. In 4 (29%) of DoCE cases, optical coherence tomography confirmed the Mg-BRS collapse and uncontrolled dismantling., Conclusion: In contradiction to earlier studies, we encountered a relatively high rate of DoCEs in an all-comer cohort treated with the Mg-BRS. We even observed scaffold collapse and uncontrolled dismantling. This implicates that this metal-based BRS requires further investigation and may only be used in highly selected cases., Competing Interests: MB has received speaker and/or consultant fees from Abbott Vascular, Amgen, AstraZeneca, Abiomed, Amgen, Bayer, Daiichi Sankyo, Mundipharma, and SIS Medical. RK has received institutional grants from Abbott, Biosense Webster, Biotronik, Boston Scientific, Medtronic, and SIS Medical and serves as a consultant for Biosense Webster and Biotronik. FC has received speaker and consulting fees from Abbott Vascular, Abiomed, and SIS Medical. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Bossard, Madanchi, Avdijaj, Attinger-Toller, Cioffi, Seiler, Tersalvi, Kobza, Schüpfer and Cuculi.)
- Published
- 2022
- Full Text
- View/download PDF
37. Ventricular Unloading Using the Impella TM Device in Cardiogenic Shock.
- Author
-
Attinger-Toller A, Bossard M, Cioffi GM, Tersalvi G, Madanchi M, Bloch A, Kobza R, and Cuculi F
- Abstract
Cardiogenic shock (CS) remains a leading cause of hospital death. However, the use of mechanical circulatory support has fundamentally changed CS management over the last decade and is rapidly increasing. In contrast to extracorporeal membrane oxygenation as well as counterpulsation with an intraaortic balloon pump, ventricular unloading by the Impella™ device actively reduces ventricular volume as well as pressure and augments systemic blood flow at the same time. By improving myocardial oxygen supply and enhancing systemic circulation, the Impella device potentially protects myocardium, facilitates ventricular recovery and may interrupt the shock spiral. So far, the evidence supporting the use of Impella™ in CS patients derives mostly from observational studies, and there is a need for adequate randomized trials. However, the Impella™ device appears a promising technology for management of CS patients. But a profound understanding of the device, its physiologic impact and clinical application are all important when evaluating CS patients for percutaneous circulatory support. This review provides a comprehensive overview of the percutaneous assist device Impella™. Moreover, it highlights in depth the rationale for ventricular unloading in CS and describes practical aspects to optimize care for patients requiring hemodynamic support., Competing Interests: MB has received speaker fees from Abbott Vascular, Abiomed, and SIS Medical. FC has received speaker and/or consultant fees from Abbott Vascular, Abiomed, Boston Scientific, and SIS Medical. RK has received institutional grants from Abbott, Biosense-Webster, Biotronik, Boston, Medtronic, SIS Medical, and consultant fees from Biosense-Webster and Biotronik. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Attinger-Toller, Bossard, Cioffi, Tersalvi, Madanchi, Bloch, Kobza and Cuculi.)
- Published
- 2022
- Full Text
- View/download PDF
38. Metal free percutaneous coronary interventions in all-comers: First experience with a novel sirolimus-coated balloon.
- Author
-
Madanchi M, Cioffi GM, Attinger-Toller A, Seiler T, Somm S, Koch T, Tersalvi G, Wolfrum M, Moccetti F, Toggweiler S, Kobza R, Levine MB, Garcia-Garcia HM, Bossard M, and Cuculi F
- Subjects
- Humans, Middle Aged, Aged, Sirolimus adverse effects, Prospective Studies, Treatment Outcome, Metals, Coronary Angiography, Percutaneous Coronary Intervention adverse effects, Drug-Eluting Stents, Coronary Restenosis diagnostic imaging, Coronary Restenosis etiology, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery
- Abstract
Background: Limus-eluting stents have become the mainstay for percutaneous coronary intervention (PCI). However, even with the latest generation drug-eluting stent, in-stent restenosis and very late stent thrombosis remain a concern. The Selution SLR™ drug-coated balloon (DCB) is a novel sirolimus-coated balloon that provides a controlled release of the antiproliferative drug. Herein we evaluated its performance in a real-world patient cohort with complex coronary artery lesions., Methods: Patients undergoing PCI using the Selution SLR™ DCB were analyzed from the prospective SIROOP registry. We evaluated procedural success and clinical outcomes, including major adverse cardiovascular event (MACE), cardiac death, target vessel myocardial infarction and target lesion revascularization., Results: From September 2020 to April 2021, we enrolled 78 patients (87 lesions) treated using a "DCB only" strategy. The mean age was 66.7 ± 10.4 years and 28 (36%) presented with an acute coronary syndrome. Almost all lesions were type B2/C 86 (99%) and 49 (63%) had moderate to severe calcifications. Procedural success was 100%. After a median follow-up of 11.2 months (interquartile range: 10.0-12.6), MACE occurred in 5 (6.8%) patients. No acute vessel closure was observed., Conclusions: In complex coronary lesions, a "DCB only" strategy using the Selution SLR™ DCB is not just safe and feasible, but also seems to be associated with a low rate of MACE at 1-year follow-up. Our promising results warrant further evaluation in a dedicated comparative trial.
- Published
- 2022
- Full Text
- View/download PDF
39. Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold.
- Author
-
Madanchi M, Cioffi GM, Attinger-Toller A, Wolfrum M, Moccetti F, Seiler T, Vercelli L, Burkart P, Toggweiler S, Kobza R, Bossard M, and Cuculi F
- Subjects
- Aged, Coronary Angiography methods, Coronary Restenosis diagnosis, Coronary Restenosis etiology, Female, Follow-Up Studies, Graft Occlusion, Vascular complications, Graft Occlusion, Vascular diagnosis, Humans, Immunosuppressive Agents pharmacology, Male, Propensity Score, Retrospective Studies, Time Factors, Tissue Scaffolds, Treatment Outcome, Absorbable Implants, Coronary Restenosis surgery, Drug-Eluting Stents, Everolimus pharmacology, Graft Occlusion, Vascular surgery, Percutaneous Coronary Intervention methods, Registries
- Abstract
Background: Early studies evaluating the performance of bioresorbable scaffold (BRS) Absorb in in-stent restenosis (ISR) lesions indicated promising short-term to mid-term outcomes., Aims: To evaluate long-term outcomes (up to 5 years) of patients with ISR treated with the Absorb BRS., Methods: We did an observational analysis of long-term outcomes of patients treated for ISR using the Absorb BRS (Abbott Vascular, Santa Clara, California, USA) between 2013 and 2016 at the Heart Centre Luzern. The main outcomes included a device-oriented composite endpoint (DOCE), defined as composite of cardiac death, target vessel (TV) myocardial infarction and TV revascularisation, target lesion revascularisation and scaffold thrombosis (ScT)., Results: Overall, 118 ISR lesions were treated using totally 131 BRS among 89 patients and 31 (35%) presented with an acute coronary syndrome. The median follow-up time was 66.3 (IQR 52.3-77) months. A DOCE had occurred in 17% at 1 year, 27% at 2 years and 40% at 5 years of all patients treated for ISR using Absorb. ScTs were observed in six (8.4%) of the cohort at 5 years., Conclusions: Treatment of ISR using the everolimus-eluting BRS Absorb resulted in high rates of DOCE at 5 years. Interestingly, while event rates were low in the first year, there was a massive increase of DOCE between 1 and 5 years after scaffold implantation. With respect to its complexity, involving also a more unpredictable vascular healing process, current and future BRS should be used very restrictively for the treatment of ISR., Competing Interests: Competing interests: MM, GMC, AA-T, MW, FM, TS, LV, ST and RK report no conflicts of interest. MB has received consulting and speaker fees from Amgen, Astra Zeneca, Bayer and Mundipharma. FC has received consulting and speaker fees from SIS Medical and Abbott Vascular., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
40. The Importance of Defining the Coronary Anatomy in Suspected Myopericarditis: A Case Report.
- Author
-
Madanchi M, Cioffi GM, Kobza R, Cuculi F, and Bossard M
- Subjects
- Adult, Chest Pain etiology, Coronary Angiography, Humans, Male, Middle Aged, Troponin, Acute Coronary Syndrome diagnostic imaging, Drug-Eluting Stents
- Abstract
BACKGROUND It is challenging to distinguish between acute coronary syndrome (ACS) and myocardial injury due to alternative causes (eg myopericarditis, coronary vasospasm, and pulmonary embolism), as they often share similar presentations, especially in young patients. Coronary computerized tomography angiography (CCTA) is increasingly recognized as a fast and safe diagnostic tool for rapid assessment of the coronary anatomy among patients with a low to intermediate cardiovascular risk profile and/or atypical chest pain. However, its utility among patients with possible ACS is still debated. CASE REPORT A 36-year-old man presented to our institution with intermittent pleuritic chest pain and malaise over the preceding 7 days. He was a smoker and his father had ACS at the age of 45 years. The patient had unspecific electrocardiographic changes and elevated troponin values. The initial transthoracic echocardiogram indicated a normal ejection fraction without any wall motion abnormalities. Presuming a very low chance of coronary artery disease due to his age and atypical symptoms, we ordered a CCTA, which identified a thrombotic lesion in the right coronary artery (RCA). An invasive coronary angiography, including an optical coherence tomography, confirmed the presence of a thrombotic lesion located at the level of the proximal RCA, which was consequently treated with 1 drug-eluting stent. CONCLUSIONS Physicians should always eliminate underlying coronary artery disease among patients with unclear myocardial injury, irrespective of a patient's presentation, age, and estimated cardiovascular risk. In this context, CCTA represents a safe and simple tool to rapidly assess the coronary anatomy, especially in younger patients.
- Published
- 2021
- Full Text
- View/download PDF
41. Deferring stent optimization in stent thrombosis: A novel approach for STEMI management-Insights from a case series.
- Author
-
Cioffi GM, Madanchi M, Bossard M, and Cuculi F
- Abstract
Treatment of ST represents a challenge. The presence of large amounts of thrombus combined with stent optimization increase the risk of distal embolization. A two-step strategy of stent implantation and deferred stent optimization might be appropriated. We hereby present three clinical cases of ST successfully treated with a two-step approach., Competing Interests: GM Cioffi and M Madanchi report no conflicts of interest. M. Bossard has received consulting and speaker fees from Amgen, Astra Zeneca, Bayer, and Mundipharma. F Cuculi has received consulting and speaker fees from SIS Medical and Abbott Vascular., (© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
42. The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort.
- Author
-
Madanchi M, Fagagnini S, Fournier N, Biedermann L, Zeitz J, Battegay E, Zimmerli L, Vavricka SR, Rogler G, and Scharl M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anemia, Iron-Deficiency etiology, Female, Folic Acid Deficiency etiology, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Prospective Studies, Switzerland epidemiology, Vitamin B 12 Deficiency etiology, Young Adult, Anemia, Iron-Deficiency epidemiology, Colitis, Ulcerative complications, Crohn Disease complications, Folic Acid Deficiency epidemiology, Vitamin B 12 Deficiency epidemiology
- Abstract
Background Andaims: Vitamin and iron deficiencies are common in patients with inflammatory bowel disease (IBD) as a result of chronic intestinal inflammation, increase in demand, or dietary restrictions. Here, we assessed the frequency of complications in relation to deficiency of iron, folate acid, and vitamin B12 in patients enrolled in the nationwide Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)., Methods: A total of 2666 patients were included in the study, 1558 with Crohn's disease (CD) and 1108 with ulcerative colitis (UC)., Results: Iron deficiency anemia was detected in 19.6% of CD patients and 21.6% of UC patients. In CD patients low BMI and nonsmoker status were positively associated with anemia. In both CD and UC, malabsorption syndrome, defined as failure of the GI tract to absorb 1 or more substances from the diet, was found to be significantly associated with anemia (6.2% and 3.8%, respectively) and current steroid use (40% CD, 52.7% UC). In CD patients with ileal (31.7% vs 20%) and colonic (29.9% vs 25%) disease location folate deficiency was significantly higher than in patients with ileocolonic CD or upper GI involvement. In CD patients, vitamin B12 deficiency was associated with the onset of stenosis and intestinal surgery (42.9% vs 32.8% and 46% vs 33% for patients with versus without B12 deficiency)., Conclusion: Our data indicate that due to frequent occurrence of deficiency states, regular monitoring and substitution of vitamins and iron are mandatory and may prevent long-term intestinal and extraintestinal complications in IBD patients.
- Published
- 2018
- Full Text
- View/download PDF
43. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience.
- Author
-
Madanchi M, Zeitz J, Barthel C, Samaras P, Scharl S, Sulz MC, Biedermann L, Frei P, Vavricka SR, Rogler G, and Scharl M
- Subjects
- Adult, Aged, Aged, 80 and over, Bile Duct Neoplasms etiology, Carcinoma, Transitional Cell etiology, Cholangiocarcinoma etiology, Colorectal Neoplasms etiology, Female, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Incidence, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases drug therapy, Lymphoma, Non-Hodgkin etiology, Male, Middle Aged, Prostatic Neoplasms etiology, Retrospective Studies, Risk Factors, Switzerland epidemiology, Urinary Bladder Neoplasms etiology, Young Adult, Bile Duct Neoplasms epidemiology, Carcinoma, Transitional Cell epidemiology, Cholangiocarcinoma epidemiology, Colorectal Neoplasms epidemiology, Inflammatory Bowel Diseases epidemiology, Lymphoma, Non-Hodgkin epidemiology, Prostatic Neoplasms epidemiology, Urinary Bladder Neoplasms epidemiology
- Abstract
Background: Gastrointestinal and extraintestinal malignancies are long-term complications in patients with inflammatory bowel disease (IBD), likely as a result of chronic inflammation and the use of immunosuppressive medications used to control inflammation. Here, we assessed the frequency of malignancies in a large tertiary IBD centre at the University Hospital Zurich., Methods: We performed a retrospective analysis of data from 1,026 patients from our IBD clinic treated between 2007 and 2014., Results: Twenty two of the 1,026 patients developed 28 cases of malignancies, 14 patients were male and 8 patients female. The median latency between IBD diagnosis and first malignancy was 13 years (range 2-27 years). Most common malignancies were non-Hodgkin lymphoma, colorectal cancer (CRC), urothelial carcinoma, cholangiocellular carcinoma (CCC) and prostate cancer. The most common tumour type in Crohn's disease patients (13/22) was lymphoma (5 cases), in ulcerative colitis patients (9/22) CCC (2 cases) and CRC (2 cases). The observed incidence of lymphoma (32.5/100,000), bladder carcinoma (21.7/100,000) and CCC (10.8/100,000) was higher than expected and known from general population. All of the patients that developed a malignancy had received immunosuppressive therapy. Compared to a cohort of 927 IBD patients without malignancies there were no statistical differences regarding gender, antibodies targeting tumour necrosis factor and thiopurine use., Conclusion: Our data support the assumption that a long-standing disease course and immunosuppressive therapy increase the risk for developing malignancies in IBD patients., (© 2016 S. Karger AG, Basel.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.